Efficacy Evaluation of an Intradermally Delivered Enterotoxigenic Escherichia coli CF Antigen I Fimbrial Tip Adhesin Vaccine Coadministered with Heat-Labile Enterotoxin with LT(R192G) against Experimental Challenge with Enterotoxigenic E. coli H10407 in Healthy Adult Volunteers
Authors:
- Ramiro L. GutiérrezRGRamiro L. Gutiérrez
- Chad K. PorterCPChad K. Porter
- Clayton HarroCHClayton Harro
- Kawsar TalaatKTKawsar Talaat
- Mark S. RiddleMRMark S. Riddle
- Barbara DeNearingBDBarbara DeNearing
- Jessica BrubakerJBJessica Brubaker
- Milton MacielMMMilton Maciel
- Renee M. LairdRLRenee M. Laird
- Steven PooleSPSteven Poole
- Subra ChakrabortySCSubra Chakraborty
- Nicole MaierNMNicole Maier
Open Access
- 29 January 2024
- journal article
- research article
- Published by MDPI AG in Microorganisms
- Vol. 12 (2) , 288
Abstract
Background. Enterotoxigenic E. coli (ETEC) is a principal cause of diarrhea in travelers, deployed military personnel, and children living in low to middle-income countries. ETEC expresses a variety of virulence factors including colonization factors (CF) that facilitate adherence to the intestinal mucosa. We assessed the protective efficacy of a tip-localized subunit of CF antigen I (CFA/I), CfaE, delivered intradermally with the mutant E. coli heat-labile enterotoxin, LTR192G, in a controlled human infection model (CHIM). Methods. Three cohorts of healthy adult subjects were enrolled and given three doses of 25 μg CfaE + 100 ng LTR192G vaccine intradermally at 3-week intervals. Approximately 28 days after the last vaccination, vaccinated and unvaccinated subjects were admitted as inpatients and challenged with approximately 2 × 107 cfu of CFA/I+ ETEC strain H10407 following an overnight fast. Subjects were assessed for moderate-to-severe diarrhea for 5 days post-challenge. Results. A total of 52 volunteers received all three vaccinations; 41 vaccinated and 43 unvaccinated subjects were challenged and assessed for moderate-to-severe diarrhea. Naïve attack rates varied from 45.5% to 64.7% across the cohorts yielding an overall efficacy estimate of 27.8% (95% confidence intervals: −7.5–51.6%). In addition to reducing moderate–severe diarrhea rates, the vaccine significantly reduced loose stool output and overall ETEC disease severity. Conclusions. This is the first study to demonstrate protection against ETEC challenge after intradermal vaccination with an ETEC adhesin. Further examination of the challenge methodology is necessary to address the variability in naïve attack rate observed among the three cohorts in the present study.Keywords
Funding Information
- Military Infectious Diseases Research Program (OPP1112376)
- Navy Advanced Development Program (OPP1112376)
- Bill and Melinda Gates Foundation (OPP1112376)
This publication has 39 references indexed in Scilit:
- Immunogenicity of a prototype enterotoxigenic Escherichia coli adhesin vaccine in mice and nonhuman primatesVaccine, 2016
- Maternal Vaccination with a Fimbrial Tip Adhesin and Passive Protection of Neonatal Mice against Lethal Human Enterotoxigenic Escherichia coli ChallengeInfection and Immunity, 2015
- Recent Advances in Understanding Enteric Pathogenic Escherichia coliClinical Microbiology Reviews, 2013
- Quantifying the Incidence and Burden of Postinfectious Enteric SequelaeMilitary Medicine, 2013
- Refinement of a Human Challenge Model for Evaluation of Enterotoxigenic Escherichia coli VaccinesClinical and Vaccine Immunology, 2011
- A systematic review of experimental infections with enterotoxigenic Escherichia coli (ETEC)Vaccine, 2011
- A systematic review of ETEC epidemiology focusing on colonization factor and toxin expressionVaccine, 2011
- CfaE tip mutations in enterotoxigenicEscherichia coliCFA/I fimbriae define critical human intestinal binding sitesCellular Microbiology, 2009
- Donor strand complementation governs intersubunit interaction of fimbriae of the alternate chaperone pathwayMolecular Microbiology, 2007
- Group sequential methods in the design and analysis of clinical trialsBiometrika, 1977